Claims
- 1. An antisense compound 8 to 30 nucleotides in length targeted to a nucleic acid molecule encoding a human tumor necrosis factor receptor-associated factor, wherein said antisense compound inhibits the expression of human tumor necrosis factor receptor-associated factor.
- 2. The antisense compound of claim 1 which is an antisense oligonucleotide.
- 3. The antisense oligonucleotide of claim 2 which comprises at least one modified internucleoside linkage.
- 4. The antisense oligonucleotide of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.
- 5. The antisense oligonucleotide of claim 2 which comprises at least one modified sugar moiety.
- 6. The antisense oligonucleotide of claim 5 wherein the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.
- 7. The antisense oligonucleotide of claim 2 which comprises at least one modified nucleobase.
- 8. The antisense oligonucleotide of claim 7 wherein the modified nucleobase is a 5-methylcytosine.
- 9. The antisense compound of claim 1 which is a chimeric oligonucleotide.
- 10. The antisense compound of claim 1 wherein the human TRAF is TRAF-2 or TRAF-6.
- 11. A pharmaceutical composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
- 12. The pharmaceutical composition of claim 11 comprising a colloidal dispersion system.
- 13. The pharmaceutical composition of claim 11 wherein the antisense compound is an antisense oligonucleotide.
- 14. A method of inhibiting the expression of tumor necrosis factor receptor-associated factor in human cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of tumor necrosis factor receptor-associated factor is inhibited.
- 15. A method of reducing jun kinase activation in cells or tissues by tumor necrosis factor-α comprising contacting said cells or tissues with an antisense compound targeted to TRAF-2.
- 16. A method of reducing jun kinase activation in cells or tissues comprising contacting said cells or tissues with an antisense compound targeted to TRAF-6.
- 17. A method of reducing E-selectin expression in cells or tissues comprising contacting said cells or tissues with an antisense compound targeted to TRAF-2 or TRAF-6.
BACKGROUND
[0001] This application is is a continuation of U.S. patent application Ser. No. 09/167,109 filed Oct. 6, 1998.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09167109 |
Oct 1998 |
US |
Child |
10067125 |
Feb 2002 |
US |